AiCuris Anti-infective Cures GmbH

AMR Stakeholder Profile​

AiCuris Anti-infective Cures GmbH

AiCuris

Focus area/active in: Therapeutics

Company/Organisation type: Industry

About:
AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases. SANTO Holding is the Company’s majority investor. PREVYMIS® (Letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, the USA, Japan and other parts of the world for use in bone marrow transplants for the prevention of HCMV infections in adults who receive an allogeneic hematopoietic stem cell transplant. The Company is developing drugs for the treatment of viruses such as human CMV, herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multidrug-resistant, hospital-treated pathogens.
In 2018 Prof. Dr. Helga Rübsamen-Schaeff, Founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris, were awarded the German Future Prize 2018 (German President’s Award for Innovation in Science and Technology) for the development of Letermovir and their project, “Protection in the Absence of the Immune System – a Life-Saving Innovation against Dangerous Viruses” (original title: “Schutz bei fehlendem Immunsystem – die lebensrettende Innovation gegen gefährliche Viren”).

Website: www.aicuris.com/

Partnering

Would you like to meet AiCuris Anti-infective Cures GmbH virtually during the AMR Conference week?

Get in touch!

Igor Orshanskiy
Associate Director, Business Development and Alliance Management
AiCuris Anti-infective Cures GmbH

Please fill out the form below to get in touch with us.

Share this page:

Share on twitter
Twitter
Share on linkedin
LinkedIn